Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 5,930,159 | 5,485,019 | 5,866,049 | 5,228,167 | 5,054,708 |
| Marketable Securities | 143,952 | 103,583 | 145,562 | 185,325 | 129,419 |
| Receivables | 7,236,176 | 7,582,020 | 7,221,273 | 7,839,578 | 7,493,354 |
| Inventories | 6,988,731 | 7,062,215 | 6,988,311 | 7,372,337 | 7,819,812 |
| Other current assets | 4,001,262 | 2,782,463 | 2,497,575 | 2,561,583 | 1,584,997 |
| TOTAL | $24,300,280 | $23,015,300 | $22,718,770 | $23,186,990 | $22,082,290 |
| Non-Current Assets | |||||
| PPE Net | 12,849,330 | 12,705,450 | 12,754,600 | 13,513,350 | 13,550,660 |
| Investments And Advances | 3,286,259 | 3,130,733 | 3,398,986 | 3,629,694 | 3,260,375 |
| Intangibles | 72,703,400 | 74,655,070 | 75,291,780 | 77,395,410 | 78,628,760 |
| Other Non-Current Assets | 3,559,351 | 3,802,267 | 3,789,934 | 2,164,306 | 2,263,225 |
| TOTAL | $92,398,340 | $94,293,520 | $95,235,300 | $96,702,760 | $97,703,020 |
| Total Assets | $116,698,600 | $117,308,800 | $117,954,100 | $119,889,700 | $119,785,300 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 2,600,190 | 5,400,808 | 5,398,716 | 5,627,649 | 1,593,936 |
| Accounts payable and accrued liabilities | 2,564,113 | 2,694,591 | 2,933,107 | 2,759,006 | 2,607,804 |
| Other current liabilities | 9,546,227 | 9,128,518 | 10,005,250 | 9,785,948 | 9,366,365 |
| TOTAL | $16,070,810 | $18,893,360 | $20,018,260 | $19,571,760 | $15,202,100 |
| Non-Current Liabilities | |||||
| Long Term Debt | 43,535,330 | 41,796,290 | 41,459,680 | 42,412,480 | 45,134,940 |
| Other Non-Current Liabilities | 7,240,727 | 6,611,625 | 6,451,392 | 6,661,211 | 6,678,425 |
| TOTAL | $56,762,710 | $54,791,360 | $54,442,930 | $55,456,770 | $59,295,160 |
| Total Liabilities | $72,833,530 | $73,684,720 | $74,461,200 | $75,028,530 | $74,497,250 |
| Shareholders' Equity | |||||
| Common Shares | 15,680,560 | 15,513,750 | 15,346,730 | 15,346,450 | 15,513,260 |
| Retained earnings | 12,568,410 | 12,369,500 | 12,603,740 | 12,681,710 | 13,741,580 |
| Other shareholders' equity | 488,720 | 854,150 | 888,760 | 2,239,760 | 1,348,110 |
| TOTAL | $43,865,090 | $43,624,110 | $43,492,870 | $44,861,210 | $45,288,060 |
| Total Liabilities And Equity | $116,698,620 | $117,308,830 | $117,954,070 | $119,889,740 | $119,785,310 |